Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer

被引：0
|
作者：
Schmoll, H.
Tabernero, J.
Nowacki, M.
Maroun, J.
Price, T.
Lim, R.
Van Cutsem, E.
de Braud, F.
Haller, D.
机构：
[1] Univ Halle Wittenberg, Halle, K1Y 4K7, Germany
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Maria Sklodowska Curie Mem Canc Ctr, Inst Oncol, Warsaw 117548, Poland
[4] Ottawa Reg Canc Ctr, B-3000 Ottawa, ON, Canada
[5] Queen Elizabeth Hosp, Adelaide, SA, Australia
[6] Natl Univ Singapore Hosp, Singapore, 19104, Singapore
[7] Univ Hosp Gasthuisberg, Louvain, Belgium
[8] Ist Europeo Oncol, Milan, Italy
[9] Univ Penn, Philadelphia, PA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [41] Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
    Katsuki Danno
    Taishi Hata
    Koki Tamai
    Yujiro Fujie
    Yoshihito Ide
    Ho Min Kim
    Tadashi Ohnishi
    Shunji Morita
    Shinichi Yoshioka
    Toshihiro Kudo
    Junichi Nishimura
    Chu Matsuda
    Hiroki Akamatsu
    Tsunekazu Mizushima
    Riichiro Nezu
    Yuichiro Doki
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 777 - 785
  • [42] Phase III trial of capecitabine plus oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC)
    Rothenberg, M. L.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J. V.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis.
    Ducreux, M
    Adenis, A
    Bennouna, J
    Conroy, T
    Faroux, R
    Hebbar, M
    Lledo, G
    Paillot, B
    Ychou, M
    Douillard, JY
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 270S - 270S
  • [44] Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for Dukes' C colon cancer: No differences in treatment arms that could influence survival outcome.
    Cassidy, J
    Koralewski, P
    Husseini, F
    Twelves, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 267S - 267S
  • [45] Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer
    Arnold, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (02) : 196 - 197
  • [46] Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
    Haller, Daniel G.
    Tabernero, Josep
    Maroun, Jean
    de Braud, Filippo
    Price, Timothy
    Van Cutsem, Eric
    Hill, Mark
    Gilberg, Frank
    Rittweger, Karen
    Schmoll, Hans-Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) : 1465 - 1471
  • [47] Two Pan-European trials in adjuvant colon cancer (PETACC 1&2):: The efficacy of Tomudex® compared to bolus 5-Fluorouracil/leucovorin (5-FU/LV); and high dose infusional 5-FU compared to bolus 5-FU/LV, in patients with stage III colon cancer
    Wils, J
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [48] Safety and quality of life (QoL) findings from a randomized phase III study of capecitabine (X) plus oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) in metastatic colorectal cancer (MCRC)
    Hebbar, M.
    Bennouna, J.
    Boige, V.
    Ychou, M.
    Lledo, G.
    Adenis, A.
    Faroux, R.
    Rebischung, C.
    Douillard, J.
    Conroy, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE plus OXALIPLATIN) VERSUS FOLFOX-4 (5-FU/LV + OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Prolla, G.
    Borges, L. G.
    Santos, E.
    VALUE IN HEALTH, 2010, 13 (07) : A268 - A269
  • [50] Updated safety findings from a randomized phase II trial of capecitabine plus epirubicin plus cyclophosphamide (CEX) vs. 5-FU plus epirubicin plus cyclophosphamide (FEC) as neoadjuvant therapy in patients (pts) with operable breast cancer (BC)
    Roche, Henri
    Deporte, Regine
    Berton-Rigaud, Dominique
    Coudert, Bruno
    Tubiana-Mathieu, Nicole
    Ferrero, Jean Marc
    Orfeuvre, Hubert
    Audhuy, Bruno
    Dalenc, Florence
    Fumoleau, Pierre
    ANNALS OF ONCOLOGY, 2006, 17 : 99 - 99
12345